Correspondence 0001104659-24-083031 from ACTUATE THERAPEUTICS, INC. (ACTU)
ACTUATE THERAPEUTICS, INC.
Date: July 26, 2024 · CIK: 0001652935 · Accession: 0001104659-24-083031
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-279734
Letter
Actuate Therapeutics, Inc.
1751 River Run, Suite 400
Fort Worth, TX 76107
July 26, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Eric Attalah, Kevin Kuhar, Jessica Dickerson and Tim Buchmiller
Re: Actuate Therapeutics, Inc.
Registration Statement on Form S-1
File No. 333-279734
Ladies and Gentlemen:
Reference is made to our letter, filed as correspondence via EDGAR on July 19, 2024, in which we requested the acceleration of the effective date of the above-referenced registration statement (the “Registration Statement”) for July 23, 2024 at 4:30 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Baker & Hostetler LLP, requested by telephone that such Registration Statement be declared effective at some other time, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such Registration Statement be declared effective at that date and time and we hereby formally withdraw our request for acceleration of the effective date.
If you have any questions regarding this request, please contact Janet Spreen of Baker & Hostetler LLP, counsel to the Company, at (216) 861-7564.
Very truly yours,
Actuate Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Actuate
Therapeutics, Inc.
1751 River Run, Suite 400
Fort Worth, TX 76107
July 26, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Eric Attalah, Kevin Kuhar, Jessica Dickerson and Tim Buchmiller
Re: Actuate Therapeutics, Inc.
Registration Statement on Form S-1
File No. 333-279734
Ladies and Gentlemen:
Reference is made to our letter,
filed as correspondence via EDGAR on July 19, 2024, in which we requested the acceleration of the effective date of the above-referenced
registration statement (the “Registration Statement”) for July 23, 2024 at 4:30 p.m., Eastern Time, or as soon
thereafter as practicable, unless we or our outside counsel, Baker & Hostetler LLP, requested by telephone that such Registration
Statement be declared effective at some other time, in accordance with Rule 461 under the Securities Act of 1933, as amended. We
are no longer requesting that such Registration Statement be declared effective at that date and time and we hereby formally withdraw
our request for acceleration of the effective date.
If you have any questions
regarding this request, please contact Janet Spreen of Baker & Hostetler LLP, counsel to the Company, at (216) 861-7564.
Very truly yours,
Actuate Therapeutics, Inc.
By:
/s/
Daniel M. Schmitt
Daniel M. Schmitt
President and Chief Executive
Officer